This story by STAT covers a study of a treatment for prostate cancer that comes back after initial rounds of surgery and radiation. The treatment is hormone blocking, or androgen deprivation therapy, and its side effects are significant. In this review, we’ll occasionally compare the coverage to The New York Times’ story about the same study (see that story review here), since it highlights a few important ways reporters and their outlets deviate in their coverage of important research.
Here, STAT does a good job of succinctly describing what is novel about this study and for which patients it may be relevant. It also was very clear on who funded the research.
Its main shortcoming is that while it does a good job of presenting the results as an incremental step forward, it presents results in relative terms rather than absolute (read here why that matters). It states that the study decreased death rates by half (50%) rather than saying that survival was improved by 5% (76% vs. 71%). This is a clear example of how presenting relative versus absolute outcomes can skew one’s interpretation of a study’s results. The Times (link) handled this better.
For men who have had prostate cancer return after surgery, this study’s findings will help them make more informed decisions when choosing a treatment path. But it’s a complicated study with plenty of nuances, and this story would have been much stronger had it gotten into the absolute findings of the intervention.
No treatment costs are shown, for either radiation or hormone blocking. According to a 2015 study in the journal Future Oncology, the average cost per hospital stay was $12,268, while outpatient clinic visits tallied about $4,364 per visit (surgery and radiation). However, given multiple visits, the typical prostate cancer patient can expect a lifetime cost of about $110,000.
But adding in hormone blockers, also called androgen deprivation therapy, according to a 2007 study in The Journal of Urology, can double the cost of a man’s care. Newer drugs that are being used now might cost more, too.
We’re told the death rate over 12 years “halved” for men who received the hormone blockers, but this doesn’t reveal the full story.
The story that ran in The New York Times does a better of explaining the results in absolute terms: 76.3% of men who got the combo radiation-hormone blocker treatment lived after 12 years, whereas 71.3% of those who received radiation alone survived 12 years after a recurrence of prostate cancer.
STAT does not mention any negative side effects (including hot flashes and sexual problems).
The story provides some clues here, but not enough. How many men were enrolled? How long did patients receive the treatments? Was there a placebo? What were the limitations?
The story did not disease monger, and made sure to discuss that some men won’t need treatment.
An independent source was included. And this STAT story noted an important detail that the NYTimes missed: how AstraZeneca — a maker of a hormone-blocking drug for men — was a study sponsor.
Readers get a solid description of the standard of care, including typical procedures in the first occurrence, and how radiation therapy is typically used after a recurrence. Hormone blockers are not oversold as some revolutionary new advancement, but an existing treatment that needed long-term study to determine if they were beneficial.
The story implies hormone blockers have been around as a technique for decades, but have not been widely used due to their side effects and uncertainty surrounding their actual efficacy.
STAT is straightforward in its headline: This is an old drug, but this use is novel. An outside source helps put into context the results, calling it an “incremental” step for doctors — a more careful position than The Times’ outside source take (he calls it “a big deal;” see our review).
We didn’t find any evidence of reliance on a news release.
Systematic, Criteria-Driven
Media coverage of a recent study is generating unwarranted hype about supplemental screening for cancer for women with dense breasts. https://lowninstitute.org/news/blog/media-misleads-on-mri-screening-for-breast-cancer/
Happy to see that my @HealthNewsRevu blog about progression-free survival confusion has been reposted by @kevinmd. https://www.kevinmd.com/blog/2019/12/most-new-cancer-treatments-havent-been-proven-to-help-patients-live-longer-or-feel-better.html via @kevinmd
We are all worse off for not having @garyschwitzer's excellent, daily health care reporting, but his story today should sound the alarms and be a warning to anyone who gets health care information from local TV health news (read: much of America) (1/2) https://www.healthnewsreview.org/2019/11/why-hire-a-full-time-health-reporter-when-you-can-buy-news-off-the-shelf/#.Xeank0LWjyA.twitter
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like